Aslan’s change of course on eczema asset brings flexibility for future deals

Aslan's decision to restructure an existing deal with CSL for atopic dermatitis candidate ASLAN004, extending the partnership's scope to give the biotech full commercial rights, is part of Aslan's broader intention to gain flexibility for potential deals in the future.

Although the latest deal is reminiscent of decisions by Aslan Ltd. (TPEx:6497; NASDAQ:ASLN) to renegotiate expanded rights agreements for other programs -- part of a shift in its overall business

Read the full 691 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers